Angiotech Licenses Rex Medical Device

Angiotech Pharmaceuticals has entered a definitive licensing agreement with Rex Medical for exclusive worldwide rights to the Option inferior vena cava (IVC) filter, a medical device to prevent pulmonary embolism.

The filter was developed by Rex and is expected to be approved for both permanent and retrievable indications by the FDA, according to the company.

Rex Medical anticipates completing enrollment of its study of the filter in pulmonary embolism patients by the end of the second quarter of the year. It also has filed for CE Marking approval in Europe.